Research map: Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

Back to the article

Papers in this map

  1. The pro- and anti-inflammatory properties of the cytokine interleukin-6 · Jürgen Scheller · 2011 · 3248 citations · Cited by this paper
  2. Cutaneous IgA Vasculitis in Primary Sjögren Disease: Findings From a Medical Record–Based Review · 2026 · Related
  3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  4. International Myositis Assessment and Clinical Studies Guidelines for Risk‐Based Cancer Screening: An External Validation in Patients With Dermatomyositis Seen at a Metropolitan Academic Center · 2026 · Related
  5. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo · Raja Narayana Atreya · 2000 · 1301 citations · Cited by this paper
  6. How Do Open‐Ended Interview and Closed‐Ended Questionnaire Responses Compare? A Matched Mixed‐Methods Study Examining Treatment Attitudes of Patients With Meniscal Tear and Persistent Pain · 2026 · Related
  7. Immune-checkpoint inhibitors: long-term implications of toxicity · Douglas Buckner Johnson · 2022 · 971 citations · Cited by this paper
  8. Limitations of Hemophagocytic Lymphohistiocytosis Diagnostic Scoring in a Patient With Cirrhosis on Ursodiol: A Case Report · 2026 · Related
  9. Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature · Laura C. Cappelli · 2016 · 404 citations · Cited by this paper
  10. Comparison of Rule‐Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records · 2026 · Related
  11. Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer · Yukihiro Toi · 2018 · 374 citations · Cited by this paper
  12. Quantification of Vascular Burden on Cranial Vessel Wall Magnetic Resonance Imaging and Ophthalmic Complications in Giant Cell Arteritis · 2026 · Related
  13. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors · Marie Kostine · 2020 · 289 citations · Cited by this paper
  14. Lupus, a Leading Cause of Years of Potential Life Lost in Young Women: Implications for Public Health Priorities and Research Funding · 2026 · Related
  15. Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma · James Randall Patrinely · 2021 · 264 citations · Cited by this paper
  16. Clinical Images: Achilles tendon rupture in rheumatoid arthritis · 2026 · Related
  17. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer · Chao Liu · 2021 · 263 citations · Cited by this paper
  18. Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases · 2026 · Related
  19. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors · Adam Diehl · 2017 · 247 citations · Cited by this paper
  20. Increased Risk of Environmental and Endemic Infectious Diseases in Sjögren's Disease: A Retrospective Analysis (2015–2023) · 2026 · Related
  21. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade · Sara Valpione · 2018 · 208 citations · Cited by this paper
  22. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis · Sébastien Le Burel · 2017 · 203 citations · Cited by this paper
  23. Immune dysregulation in cancer patients developing immune-related adverse events · Shaheen Khan · 2018 · 198 citations · Cited by this paper
  24. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective · Paul Gougis · 2024 · 150 citations · Cited by this paper
  25. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis · Fausto Petrelli · 2019 · 130 citations · Cited by this paper
  26. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance · Rik Jasper Verheijden · 2023 · 118 citations · Cited by this paper
  27. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma · Olivier J. van Not · 2022 · 112 citations · Cited by this paper
  28. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events · Jia Luo · 2021 · 111 citations · Cited by this paper
  29. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events · Faisal Fa’ak · 2023 · 107 citations · Cited by this paper
  30. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab · Yasuhiro Fujisawa · 2017 · 104 citations · Cited by this paper
  31. C-reactive protein as an early marker of immune-related adverse events · Amir-Reza Abolhassani · 2019 · 99 citations · Cited by this paper
  32. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events · Íñigo Les · 2023 · 99 citations · Cited by this paper
  33. How to manage patients with corticosteroids in oncology in the era of immunotherapy? · Mihaela D. Aldea · 2020 · 92 citations · Cited by this paper
  34. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors · Shoiab Bukhari · 2022 · 87 citations · Cited by this paper
  35. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update · Kylie A. Fletcher · 2024 · 85 citations · Cited by this paper
  36. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy · Noha Abdel‐Wahab · 2019 · 82 citations · Cited by this paper
  37. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients · Sander Bins · 2018 · 70 citations · Cited by this paper
  38. Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis · Runci Wang · 2023 · 68 citations · Cited by this paper
  39. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma · Renáta Váraljai · 2023 · 68 citations · Cited by this paper

Source: OpenAlex (CC0)